Efficient Modification of the CCR5 Locus in Primary Human T Cells With megaTAL Nuclease Establishes HIV-1 Resistance

[1]  Beau R. Webber,et al.  Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. , 2016, Molecular Therapy.

[2]  A. Scharenberg,et al.  Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template , 2015, Science Translational Medicine.

[3]  T. Ndung’u,et al.  Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor , 2015, Proceedings of the National Academy of Sciences.

[4]  S. Rosenberg,et al.  Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity , 2015, Journal of Virology.

[5]  R. Remien,et al.  Optimizing ART Adherence: Update for HIV Treatment and Prevention , 2014, Current HIV/AIDS Reports.

[6]  Emily B Hanhauser,et al.  Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation , 2014, Annals of Internal Medicine.

[7]  Jang-Gi Choi,et al.  CCR5 Gene Editing of Resting CD4+ T Cells by Transient ZFN Expression From HIV Envelope Pseudotyped Nonintegrating Lentivirus Confers HIV-1 Resistance in Humanized Mice , 2014, Molecular therapy. Nucleic acids.

[8]  D. Schadendorf,et al.  Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. , 2014, The New England journal of medicine.

[9]  G. Marodon,et al.  Targeting both viral and host determinants of human immunodeficiency virus entry, using a new lentiviral vector coexpressing the T20 fusion inhibitor and a selective CCL5 intrakine. , 2014, Human gene therapy methods.

[10]  Summer B. Thyme,et al.  Progressive engineering of a homing endonuclease genome editing reagent for the murine X-linked immunodeficiency locus , 2014, Nucleic acids research.

[11]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[12]  K. Cornetta,et al.  Preclinical safety and efficacy of an anti–HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor , 2014, Molecular therapy. Methods & clinical development.

[13]  R. Doms,et al.  Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. , 2014, Blood.

[14]  David Baker,et al.  megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering , 2013, Nucleic acids research.

[15]  K. Sango,et al.  Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. , 2013, Virology.

[16]  R. Siliciano,et al.  Recent trends in HIV-1 drug resistance. , 2013, Current opinion in virology.

[17]  A. LaCasce,et al.  Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. , 2013, The Journal of infectious diseases.

[18]  P. Gregory,et al.  Genomic Editing of the HIV-1 Coreceptor CCR5 in Adult Hematopoietic Stem and Progenitor Cells Using Zinc Finger Nucleases , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Gabriela Plesa,et al.  Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. , 2013, Human gene therapy.

[20]  Sarah K. Baxter,et al.  Coupling endonucleases with DNA end–processing enzymes to drive gene disruption , 2012, Nature Methods.

[21]  B. Torbett,et al.  Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  Hans-Peter Kiem,et al.  Hematopoietic-stem-cell-based gene therapy for HIV disease. , 2012, Cell stem cell.

[23]  J. Church.  Evidence for the Cure of HIV Infection by CCR5δ32/Δ32 Stem Cell Transplantation , 2011, Pediatrics.

[24]  Gunnar Kvalheim,et al.  Transiently redirected T cells for adoptive transfer. , 2011, Cytotherapy.

[25]  S. Deeks,et al.  HIV infection, inflammation, immunosenescence, and aging. , 2011, Annual review of medicine.

[26]  Carl June,et al.  Chemokine receptor 5 knockout strategies , 2011, Current opinion in HIV and AIDS.

[27]  Vanessa Taupin,et al.  Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.

[28]  E. Thiel,et al.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. , 2009, The New England journal of medicine.

[29]  Summer B. Thyme,et al.  Exploitation of binding energy for catalysis and design , 2009, Nature.

[30]  Barry L. Stoddard,et al.  High-resolution profiling of homing endonuclease binding and catalytic specificity using yeast surface display , 2009, Nucleic acids research.

[31]  J. Orange,et al.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.

[32]  Brendan H. Lee,et al.  Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. , 2007, Current gene therapy.

[33]  D. McDermott,et al.  CCR5 deficiency increases risk of symptomatic West Nile virus infection , 2006, The Journal of experimental medicine.

[34]  M. Chillón,et al.  Gutless adenovirus: last-generation adenovirus for gene therapy , 2005, Gene Therapy.

[35]  Jeffrey C. Miller,et al.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.

[36]  C. June,et al.  Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. , 2005, Clinical immunology.

[37]  John Novembre,et al.  The evolutionary history of the CCR5-Δ32 HIV-resistance mutation , 2005 .

[38]  R. Samulski,et al.  Role of viral vectors and virion shells in cellular gene expression. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  Renate Kunert,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Entry in Cells Expressing gp41-Derived Peptides , 2004, Journal of Virology.

[40]  Santiago Pérez-Hoyos,et al.  Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category , 2003, AIDS.

[41]  B. Fehse,et al.  Membrane-Anchored Peptide Inhibits Human Immunodeficiency Virus Entry , 2001, Journal of Virology.

[42]  G Vassart,et al.  Extracellular Cysteines of CCR5 Are Required for Chemokine Binding, but Dispensable for HIV-1 Coreceptor Activity* , 1999, The Journal of Biological Chemistry.

[43]  J. Albert,et al.  Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates, Like HIV-1 Isolates, Frequently Use CCR5 but Show Promiscuity in Coreceptor Usage , 1999, Journal of Virology.

[44]  P. Debré,et al.  Characterization of T cell‐expressed chimeric receptors with antibody‐type specificity for the CD4 binding site of HIV‐1 gp120 , 1998, European journal of immunology.

[45]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[46]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[47]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[48]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[49]  B. Seed,et al.  Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides , 1991, Cell.

[50]  D. Markovitz,et al.  The role of mononuclear phagocytes in HTLV-III/LAV infection. , 1986, Science.

[51]  J. Novembre,et al.  The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. , 2005, Microbes and infection.

[52]  M. Carrington,et al.  Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. , 1999, Human molecular genetics.